Alpha-1 Antitrypsin Deficiency also known as Alpha-1, A1AD or AATD is an inherited, genetic condition that is passed on from generation to generation. As the name suggests it is a deficiency of alpha-1 antitrypsin (AAT) in the bloodstream. AAT is an enzyme produced in the liver to help protect the tissues of the body during infections. The low level of AAT in the blood occurs because the AAT is abnormal and cannot be released from the liver at the normal rate. This leads to a build up of abnormal AAT in the liver that can cause liver disease and a decrease of AAT in the blood that can lead to lung disease.
Breaking News - New NHS Funded Multi Disciplinary Service for Alpha-1 Patients
Specialist NHS clinics for patients with alpha 1-antitrypsin deficiency will be running in the West Midlands from the end of May 2015 to cover all aspects of alpha 1. The clinics will be run at University Hospital Coventry by Dr David Parr and at University Hospital Birmingham by Dr David Parr and Dr Alice Turner. The services at both hospitals will be run in conjunction with hepatologists (liver doctors) and dermatologists (skin doctors) and there will be close links with the transplant services and the Genetics Department at University Hospital Birmingham.
Bookings for the clinic in Coventry can be made from the end of May, and an update will follow on a start date for clinics in Birmingham. Patients wishing to be seen in either of the clinics should see their GP to arrange a referral through ‘Choose and Book’, which will enable them to book into the alpha 1 clinic of their choice. Further information can be obtained by contacting Wendi Wallace in Coventry (02476 967697) or Rebecca Bray in Birmingham (0121 3713885). The following links can also be used to access information about the two hospitals and each clinic;
Coventry - www.uhcw.nhs.uk/alpha
Birmingham - www.uhb.nhs.uk/alpha
Please Note: Birmingham web link is not live yet
The ADAPT research programme will continue to be based in Birmingham, and patients attending either NHS clinic who would also like to participate in alpha 1 research will still have the opportunity to do so.